Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Cantabio licenses U. Cambridge's tau protein IP for AD

Executive Summary

To develop potential Alzheimer's disease (AD) therapeutics, Cantabio Pharmaceuticals Inc. (formerly Gardedam Therapeutics) licensed a therapeutic program involving the tau protein from the University of Cambridge through its tech transfer arm Cambridge Enterprise Ltd.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register